Abstract：Based on the analysis of the Pharma R&D productivity crisis and deconstruction of Pharma R&D process, this article elaborates the features of Pharma R&D process and phases to get the conclusion of which the applicable type of open innovation fits each phase.At the latter part of this article, three models of Pharma R&D organization are put forward to restructure the traditional Pharma R&D organization.At the last part, the implications for government are elaborated.
[1]Oliver Scheel, Tim Wintermantel, Jim O'Keefe.Unleashing Pharma from the R&D value chain[EB/OL].http://www.atkearney.com/innovation/ideas-insights/featured-article/-/asset_publisher/BqWAk3NLsZIU/content/unleashing-pharma-from-the-r-d-value-chain/10192.1uly, 2013. [2]M.Lowman, P.Trott, A.Hoecht, et al.Innovation Risks of Outsourcing in Pharmaceutical New Product Development[J].Technovation, 2012(32):99-109.[3]Jack W.Scannell, Alex Blanckley, Helen Boldon, et al.Diagnosing the Decline in Pharmaceutical R&D Efficiency[J].Nature Reviews/Drug Discovery, 2012(11):191-200. [4]Ajay Dhankhar, Matthias Evers, Martin Moller.Escaping the Sword of Damocles:Toward a New Future for Pharmaceutical R&D[R].McKinsey perspectives on drug and device R&D 2012. [5]Jingzong Qi, Qingli Wang, Zhenhang Yu, et al.Innovative Drug R&D in China[J].Nature Reviews/Drug Discovery.2011(10):333-334. [6]Bernard Munos.Lesson form 60 Years of Pharmaceutical Innovation[J].Nature Reviews/Drug Discovery.2009(8):959-968. [7]Henry Chesbrough.Pharmaceutical Innovation Hits the Wall:How Open Innovation Can Help[EB/OL], http://www.forbes.com/sites/henrychesbrough/2011/04/25/pharmaceutical-innovation-hits-the-wall-how-open-innovation-can-help/. [8]Henry Chesbrough.Open Innovation:the New Imperative for Creating and Profiting from Technology[M].Boston:Harvard Business School Publishing Corporation.2003. [9]葛秋萍, 辜胜祖.开放式创新的国内外研究现状及展望[J].科研管理, 2011, (5). [10]Gassmann Oliver, Enkel Ellen, Towards a Theory of Open Innovation:Three Core Process Archetypes[C].Proceedings of the R&D Management Conference, 2004.Lisbon, Portugall. [11]Pricewaterhouse Coopers.Pharma 2020:challenging business models-which path will you take?.[EB/OL]www.pwc.com/pharma2020.April 2009. [12]Eric David, Amit Mehta.New Frontiers in Pharma R&D Investment[R], McKinsey Quarterly, February 2010. [13]张文强.中国产业技术创新与产学研结合的理论与实践[M], 北京:中国社会科学出版社, 2013, 09. [14]杨武.基于开放式创新的知识产权管理理论研究[J].科学学研究, 2006, (4).
2014, 
